Download PDF
Arzneimittelforschung 2011; 61(5): 317-325
DOI: 10.1055/s-0031-1296205
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-α-difluoromethyl-ornithine in plasma

Theunis T Cloete
1   Department of Pharmaceutical Chemistry, North-West University, Potchefstroom, South Africa
,
Carl C Johansson
2   Unit for Pharmacokinetics and Drug Metabolism, University of Gothenburg, Gothenburg, Sweden
,
David D N'Da
1   Department of Pharmaceutical Chemistry, North-West University, Potchefstroom, South Africa
,
Suman Kumar Vodnala
3   Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, Sweden
,
Martin E Rottenberg
3   Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, Sweden
,
Jaco C Breytenbach
1   Department of Pharmaceutical Chemistry, North-West University, Potchefstroom, South Africa
,
Michael Ashton
2   Unit for Pharmacokinetics and Drug Metabolism, University of Gothenburg, Gothenburg, Sweden
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2011 (online)

    Permissions and Reprints

Abstract

The aim of this study was to synthesize a series of mono-, di- and trisubstituted derivatives of the human African trypanosomiasis drug eflornithine (α-difluoro-methylornithine, DMFO, CAS 70052-12-9) to determine their partition coefficients, and to assess whether they deliver the parent drug in the plasma. If increased plasma concentrations of eflornithine could be achieved in this way, an oral dosage form would be possible. The derivatives, nine in total, were successfully synthesized by multi-step derivatisation of eflornithine on either its α-carboxylic or/and α-amino or/and 5-amino groups by either esterification or/and amidation or/and carbamylation, and their structures confirmed by NMR and MS spectroscopy. The majority of derivatives were more lipophilic than eflornithine with log D values in phosphate buffer solution (pH 7.4) ranging from −1.34 to 1.59 (vs. −0.98 for eflornithine). The in vivo absorption after oral administration to Sprague-Dawley rats showed that no derivative delivered eflornithine in the plasma, indicating that the derivatives were either not absorbed from the gastrointestinal tract or not metabolized to the parent drug. Two of the monosubstituted activities were toxic for T. brucei blood stream forms.

Key words

α-Difluoromethylornithine - Eflornithine derivatives - Human African trypanosomiasis (HAT) - Sleeping sickness - Trypanosoma brucei gambiense
 

  • References

  • 1 WHO. Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee. Geneva: World Health Organization 1998
    PubMedSearch in Google Scholar
  • 2 Delespaux V, de Koning H.. Drugs and drug resistance in African trypanosomiasis. Drug Resist Updates. 2007; 10: 30-50
    CrossrefPubMedSearch in Google Scholar
  • 3 Stanghellini A, Josenando T.. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health. 2001; 6: 330-4
    CrossrefPubMedSearch in Google Scholar
  • 4 Bouteille B, Oukem O, Bisser S, Dumas M.. Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol. 2003; 17: 171-81
    CrossrefPubMedSearch in Google Scholar
  • 5 Fairlamb A.. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 2003; 9: 488-94
    PubMedSearch in Google Scholar
  • 6 Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U.. Melarsoprol versus eflornithine for treating late-stage gambian trypanosomiasis in the republic of the Congo. Bull World Health Organ. 2006; 84: 783-91
    CrossrefPubMedSearch in Google Scholar
  • 7 Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud M, Checchi F.. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Trans R Soc Trop Med Hyg. 2009; 103: 280-90
    CrossrefPubMedSearch in Google Scholar
  • 8 Matovu E, Seebeck T, Enyaru JCK, Kaminsky R.. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 2001; 3: 763-70
    CrossrefPubMedSearch in Google Scholar
  • 9 Denise H, Barrett MP.. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol. 2001; 61: 1-5
    CrossrefPubMedSearch in Google Scholar
  • 10 McCann PP, Pegg AE.. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992; 54: 195-215
    CrossrefPubMedSearch in Google Scholar
  • 11 Chappuis F.. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Clin Infect Dis. 2007; 45: 1443-5
    CrossrefPubMedSearch in Google Scholar
  • 12 Iten M, Mett H, Evans A, Enyaru J, Brun R, Kaminsky R.. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-difluoromethylornithine. Antimicrob Agents Chemother. 1997; 41: 1922-5
    PubMedSearch in Google Scholar
  • 13 Burri C, Brun R.. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003; 90: S49-52
    PubMedSearch in Google Scholar
  • 14 Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, Kuzoe F. The pharmacokinetics of eflornithine (α-difluoromethylomithine) in patients with late-stage T[[dot]]b. gambiense sleeping sickness. Eur J Clin Pharmacol. 2004; 60: 269-78
    PubMedSearch in Google Scholar
  • 15 March’s Advanced Organic Chemistry: reactions, mechanisms, and structure. New York: Wiley & Sons 1992: 293-500
    PubMedSearch in Google Scholar
  • 16 Montalbetti CAGN, Falque V.. Amide bond formation and peptide coupling. Tetrahedron. 2005; 61: 10827-52
    CrossrefPubMedSearch in Google Scholar
  • 17 Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P et al Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J. 2003; 375: 465-70
    CrossrefPubMedSearch in Google Scholar
  • 18 N’Da DD, Breytenbach JC.. Synthesis of methoxypoly(ethy-lene glycol) carbonate prodrugs of zidovudine and penetration through human skin in vitro. J Pharm Pharmacol. 2009; 61: 721-31
    PubMedSearch in Google Scholar
  • 19 Jansson R, Malm M, Roth C, Ashton M.. Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. Antimicrob Agents Chemother. 2008; 52: 2842-8
    CrossrefPubMedSearch in Google Scholar
  • 20 Jansson-Löfmark R, Römsing S, Albers E, Ashton M.. Determination of eflornithine enantiomers in plasma by precolumn derivatisation with o-phthalaldehyde-N-acetyl-1-cy-steine and liquid chromatography with UV detection. Biomed Chromatogr. 2010; 24: 794-7
    CrossrefPubMedSearch in Google Scholar
  • 21 Vodnala SK, Ferella M, Lundén-Miguel H, Betha E, van Reet N, Amin DN et al Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl Trop Dis. 2009; 3 ((8)) e495
    CrossrefPubMedSearch in Google Scholar
  • 22 Chollet C, Baliani A, Barrett MP, Gilbert IH.. Targeted delivery of compounds to trypanosoma brucei using the mela-mine motif. Bioorg Med Chem. 2009; 17: 2512-23
    CrossrefPubMedSearch in Google Scholar
  • 23 Shargel L, Yu ABC. Physiologic factors related to drug absorption. In: Applied Biopharmaceutics and Pharmacokinetics. Shargel L, Yu ABC, editors. Norwalk (CT, USA): Appleton & Lange; 1999: 99-121
    PubMedSearch in Google Scholar
  • 24 Caron G, Reymond F, Carrupt P, Girault HH, Testa B.. Combined molecular lipophilicity descriptors and their role in understanding intramolecular effects. Pharm Sci Tech Today. 1999; 2: 327-35
    CrossrefPubMedSearch in Google Scholar
  • 25 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3-26
    CrossrefPubMedSearch in Google Scholar
  • 26 Ghose AK, Viswanadhan VN, Wendoloski JJ.. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999; 1: 55-68
    CrossrefPubMedSearch in Google Scholar
  • 27 Silverman RB. The organic chemistry of drug design and drug action. Amsterdam: Elsevier Academic Press; 2004
    PubMedSearch in Google Scholar
  • 28 Helena KJ, N’Da DD, Johansson CC, Breytenbach JC, Ashton M.. Effects of oral administration of synthesized δ-amides of eflornithine in the rat. Arzneimittelforschung. 2010; 60 ((11)) 682-8
    Thieme ConnectPubMedSearch in Google Scholar